Combination of | |
---|---|
Memantine | NMDA receptor antagonist |
Donepezil | Acetylcholinesterase inhibitor |
Clinical data | |
Trade names | Namzaric |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Memantine/donepezil was approved for medical use in the United States in 2014. [3]